The action of an oral high-dosed oestrogen-progestagen combination on the human breast.
D000232:Adenofibroma / Q000139:chemically induced; D000328:Adult; D001706:Biopsy; D001940:Breast / Q000187:drug effects* / Q000473:pathology; D001941:Breast Diseases / Q000139:chemically induced; D001943:Breast Neoplasms / Q000139:chemically induced; D003550:Cystic Fibrosis / Q000139:chemically induced; D004247:DNA / Q000032:analysis; D005260:Female; D006801:Humans; D007621:Karyotyping; D008234:Lynestrenol / Q000009:adverse effects* / Q000627:therapeutic use; D008598:Menstruation; D008656:Mestranol / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D012728:Sex Chromatin / Q000032:analysis; D013997:Time Factors
D004247:DNA; D008656:Mestranol; D008234:Lynestrenol